Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDES: Short-Term Anticoagulation vs Antiplatelet Therapy After LAAC
2018-003621-28Phase 3Active
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban, dabigatran, apixaban, edoxaban, clopidogrel and 1 more in Device-related thrombosis (DRT), embolism, thrombosis and 1 more (2 arms), sponsored by Institut universitaire de cardiologie et de pneumologie de Québec. Primary endpoint: Device thrombosis at 2 months. Started Apr 2019; status: active.
02
Drugs
rivaroxabandabigatranapixabanedoxabanclopidogrel
03
Conditions
Device-related thrombosis (DRT)embolismthrombosisAtrial fibrillation (AFib)
Beyond the preview
Go deeper on 2018-003621-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003621-28.